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Background: Randomized controlled trials (RCTs) indicate that long-acting bronchodilator 
combinations, such as β
2
-agonist (LABA)/muscarinic antagonist (LAMA), have favorable 
efficacy compared with commonly used COPD treatments. The objective of this analysis was to 
compare the efficacy and safety of LABA/LAMA with LAMA or LABA/inhaled corticosteroid 
(ICS) in adults with stable moderate-to-very-severe COPD.
Methods: This systematic review and meta-analysis (PubMed/MEDLINE, Embase, Cochrane 
Library and clinical trial/manufacturer databases) included RCTs comparing 12 weeks’ LABA/
LAMA treatment with LAMA and/or LABA/ICS (approved doses only). Eligible studies were 
independently selected by two authors using predefined data fields; the Preferred Reporting 
Items for Systematic Reviews and Meta-Analyses guidelines were followed.
Results: Eighteen studies (23 trials) were eligible (N=20,185). LABA/LAMA significantly 
improved trough forced expiratory volume in 1 second (FEV
1
) from baseline to week 12 versus 
both LAMA and LABA/ICS (0.07 L and 0.08 L, P0.0001), with patients more likely to achieve 
clinically important improvements in FEV
1
 of 100 mL (risk ratio [RR]: 1.33, 95% confidence 
interval [CI]: [1.20, 1.46] and RR: 1.44, 95% CI: [1.33, 1.56], respectively, the number needed to 
treat being eight and six, respectively). LABA/LAMA improved transitional dyspnea index and 
St George’s Respiratory Questionnaire scores at week 12 versus LAMA (both P0.0001), but 
not versus LABA/ICS, and reduced rescue medication use versus both (P0.0001 and P=0.001, 
respectively). LABA/LAMA significantly reduced moderate/severe exacerbation rate compared 
with LABA/ICS (RR 0.82, 95% CI: [0.75, 0.91]). Adverse event (AE) incidence was no different 
for LABA/LAMA versus LAMA treatment, but it was lower versus LABA/ICS (RR 0.94, 95% CI: 
[0.89, 0.99]), including a lower pneumonia risk (RR 0.59, 95% CI: [0.43, 0.81]). LABA/LAMA 
presented a lower risk for withdrawals due to lack of efficacy versus LAMA (RR: 0.66, 95% CI: 
[0.51, 0.87]) and due to AEs versus LABA/ICS (RR: 0.83, 95% CI: [0.69, 0.99]).
Conclusion: The greater efficacy and comparable safety profiles observed with LABA/LAMA 
combinations versus LAMA or LABA/ICS support their potential role as first-line treatment 
options in COPD. These findings are of direct relevance to clinical practice because we included 
all currently available LABA/LAMAs and comparators, only at doses approved for clinical use.
Keywords: LABA/LAMA combinations, COPD, LAMA, LABA/ICS, meta-analysis
Introduction
Long-acting bronchodilators, whether β
2
 agonists (LABAs) or muscarinic antagonists 
(LAMAs), are central to symptom management in patients with COPD.1 As well as 
improving lung function and health-related quality of life (HRQoL), they help prevent 
exacerbations and increase exercise endurance by reducing pulmonary hyperinflation 
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and dyspnea.2 LABA/inhaled corticosteroid (ICS) combina-
tions are indicated for patients with severe-to-very-severe 
COPD and a history of repeated exacerbations. Despite these 
indications, however, LABA/ICS combinations remain the 
second-most commonly prescribed first-line treatments (after 
LAMA monotherapy) across the range of COPD severities.3,4 
The use of LABA/ICS combinations has been associated 
with a decrease in the rate of COPD exacerbations but with 
an increased risk of pneumonia.5
 LAMAs and LABAs achieve bronchodilation through 
different mechanisms: muscarinic antagonists block 
acetylcholine-mediated bronchoconstriction by binding 
to M
3
 receptors in airway smooth muscle,6 whereas β
2
 
agonists induce smooth muscle relaxation by stimulating 
β
2
-adrenergic receptors.7,8 These distinct mechanisms result 
in differences in observed efficacy between the two classes 
of bronchodilators. Hence, some data suggest that LABAs 
are more effective at improving symptoms and HRQoL than 
LAMAs, while LAMAs are superior to LABAs in reducing 
exacerbations, with the differential efficacy likely occurring 
through modes of action beyond bronchodilation.8–12 Such 
differences provide the opportunity of combining LABAs and 
LAMAs in an attempt to improve treatment outcomes.
Accumulating evidence from randomized controlled 
trials (RCTs) has shown that LABA/LAMA fixed-dose 
combinations (FDCs) have beneficial effects on lung func-
tion and patient-reported outcomes compared with LAMA or 
LABA/ICS treatments, while demonstrating a similar safety 
profile.13–15 In a recent network meta-analysis, LABA/LAMA 
combinations have also been shown to be more effective than 
either of the monotherapy component in improving lung 
function, QoL, symptom scores and exacerbation rates while 
maintaining similar safety profiles.16 Building on this, the aim 
of this meta-analysis was to compare the pooled efficacy and 
safety data from trials of FDCs of LABA/LAMAs with the 
two most commonly prescribed first-line treatments: LAMAs 
and LABA/ICS combinations.
Materials and methods
literature search and terms used
Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) guidelines were used to perform this 
systematic review.17 Full details are provided in the online 
Supplementary materials.
Inclusion criteria and outcome 
assessments
Randomized, parallel-group, controlled design of 4 weeks’ 
duration, which compared LABA/LAMA FDCs with 
LAMA monotherapy or LABA/ICS combinations, were 
included. The studies were to have been conducted in adult 
patients aged 40 years with stable, moderate-to-very 
severe COPD.1
Study treatments were restricted to all currently avail-
able LABA/LAMA combinations at the approved doses of 
these combinations and their comparators (in the US or EU; 
Table S1).
Studies were required to report at least one of the fol-
lowing outcomes: trough and/or peak FEV
1
; transitional 
dyspnea index (TDI) total score; St George’s Respiratory 
Questionnaire (SGRQ) total score; rescue medication use 
(puffs/day); COPD exacerbations (as a study end point); 
safety (frequency of adverse events [AEs], serious AEs 
[SAEs] and cardiovascular events); pneumonia incidence; 
withdrawal from treatment (due to AEs or lack of efficacy); 
or deaths while on treatment.
The primary outcome was trough FEV
1
; secondary 
outcomes included peak FEV
1
, TDI, SGRQ, rescue medica-
tion use, prospectively collected annualized rate of COPD 
exacerbations, AEs and related safety measures. The effect 
of treatments was established at weeks 12, 24 or 26, and 52 
(dependent on the trial) for efficacy end points, as well as 
throughout the trial duration for safety outcomes. In addition, 
in studies in which the data were evaluated, the proportions 
of patients who achieved minimal clinically important dif-
ferences (MCIDs) in FEV
1
, TDI and SGRQ have also been 
presented; these are defined as a 100 mL increase over 
baseline for FEV
1
,18 a 1 unit increase in TDI,19 and a 4 unit 
decrease in SGRQ score.20
Data extraction and risk of bias 
assessment
Two authors (GJR and DP) reviewed the search results for 
relevant article titles meeting the inclusion criteria. The 
reviewers worked independently during study selection and 
data extraction; disagreements, if any, were resolved by 
discussion to obtain consensus.
Risk of bias of eligible trials was assessed by applying the 
Cochrane collaborations tool;21 further details are provided 
in the online Supplementary materials.
Data analysis
The meta-analysis was performed using Review Manager, 
version 5.3.5 (Copenhagen: The Nordic Cochrane Centre, 
The Cochrane Collaboration, 2014) as described in detail 
in the online Supplementary materials. In all analyses, the 
P-values were based on a two-tailed test with P0.05 con-
sidered statistically significant.
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Outcomes were pooled as forest plots using mean dif-
ferences (inverse variance [IV] or generic IV method), 
Mantel–Haenszel risk ratios (RRs) or risk differences (RDs). 
Precision of the estimates was quantified with 95% confi-
dence intervals (CIs), and heterogeneity was assessed using 
the I2 test.22 Random-effects models were used to address 
variations across studies.23
Results
studies included in the analyses
The study selection process is described in Figure 1, with fur-
ther details supplied in the online Supplementary materials. 
Eighteen studies (comprising 23 clinical trials in total) 
fulfilled the eligibility criteria, and all were included in the 
analysis (N=20,185); both reviewers were in full agreement 
as to their inclusion. Details of the studies are summarized 
in Table 1; five comprised pooled data from two clinical 
trials. One of four pharmaceutical companies (AstraZeneca, 
Boehringer Ingelheim, GlaxoSmithKline and Novartis) spon-
sored each of the studies, all of which involved randomized 
comparisons of approved doses of COPD treatments or 
placebo. Twelve of the studies compared LABA/LAMA 
with LAMA,7,15,24–33 while six compared LABA/LAMA with 
LABA/ICS (salmeterol/fluticasone propionate);34–39 two of the 
trials25,26 included two or more comparators. Further details 
for each of the studies can be found at https://ClinicalTrials.
gov/ or in their respective primary publications.7,15,24–39
Most of the studies showed a low risk of bias in the six 
items of the Cochrane instrument21 (online Supplementary 
materials; Figures S1–S3).
effect of treatments on lung function 
(trough and peak FeV1)
The overall treatment effect for each of the treatment 
comparisons are shown in Table 2 for each outcome mea-
sure at each of the protocol-defined time points. At week 
12, significant increases from baseline were observed in 
trough FEV
1
 for the LABA/LAMAs indacaterol (Ind)/
glycopyrronium (Gly) (both dose regimens), umeclidinium 
(Umec)/vilanterol (Vi) and tiotropium (Tio)/olodaterol (Olo) 
Figure 1 Study selection process: PRISMA flow diagram identifying studies included in the meta-analysis.
Abbreviation: PrIsMa, Preferred reporting Items for systematic reviews and Meta-analyses.
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relative to the respective LAMAs evaluated in their studies 
(mean differences: 0.06–0.10 L; P0.0001; Figure 2). The 
between-treatment difference for aclidinium (Acli)/formoterol 
(For) versus Acli was not statistically significantly different 
(P=0.06), but a trend in favor of Acli/For was evident.
Overall, for all LABA/LAMA versus LAMA compari-
sons, a significant improvement in trough FEV
1
 with LABA/
LAMA treatment was observed at week 12 (mean overall 
difference: 0.07 L, 95% confidence interval [CI]: [0.05, 0.09]; 
P0.0001 relative to LAMA monotherapy). This improve-
ment was maintained at weeks 24–26 and at week 52 (mean 
difference: 0.07 L, 95% CI: [0.05, 0.08], and mean difference: 
0.07 L, 95% CI: [0.05, 0.10], respectively; both P0.0001; 
Table 2; Figure S4). In addition, in studies where MCID was 
evaluated, 33% more patients receiving LABA/LAMA rather 
than LAMA treatments achieved the MCID in trough FEV
1
 
of 100 mL above baseline (RR: 1.33; 95% CI [1.20, 1.46]; 
Table 2). The number needed to treat to achieve this treatment 
benefit (NNTB) was 8 (95% CI [6, 9]; Table 2). The absolute 
proportions of patients achieving any MCID were 58% (1,018 
of 1,765) and 44% (978 of 2,240), respectively.
LABA/LAMA treatment also significantly increased 
trough FEV
1
 relative to LABA/ICS, both at the week 12 
and week 24–26 time points (overall mean differences: 
0.08 L, 95% CI: [0.07, 0.09], P0.0001; and 0.06 L, 95% 
CI: [0.00, 0.12], P=0.04, respectively; Figure 3; Table 2). 
LABA/LAMA-treated patients had a 44% greater likelihood 
of achieving an MCID in trough FEV
1
 than those receiving 
LABA/ICS (RR: 1.44; 95% CI: [1.33, 1.56]; Table 2), with 
an NNTB of 6 at week 12 (95% CI: [5, 7]; Table 2). The 
absolute proportions of patients achieving any MCID (where 
evaluated) were 59% (803 of 1,371) and 41% (562 of 1,383), 
respectively.
Peak FEV
1
 at week 12 and at weeks 24–26 was also 
higher in LABA/LAMA-treated patients versus both LAMA- 
or LABA/ICS-treated patients (overall mean differences: 
0.10–0.12 L; all P0.0001; Table 2; Figure S5).
effect of treatments on dyspnea, health 
status and rescue medication use
The effects of each treatment on dyspnea and health status 
(assessed by TDI and SGRQ, respectively), as well as rescue 
medication use, were determined at protocol-defined time 
points for individual trials and for treatment comparison 
subgroups. Overall treatment effects for all study subgroups 
combined are shown in Table 3.
TDI focal score was significantly improved in LABA/
LAMA- versus LAMA-treated patients at weeks 12 and 
24 (mean difference: 0.5 points, 95% CI: [0.32, 0.68], 
P0.0001, and mean difference: 0.29 points, 95% CI: 
[0.12, 0.46], P=0.0006, respectively; Table 3; Figure S6A). 
Furthermore, in studies wherein it was evaluated, LABA/
Table 2 effect of laBa/laMa versus laMa or laBa/ICs on trough and peak FeV1
Outcome measure Studies  
included
No of patients Estimate Effect (95% CI) I2, % 
(P-value)LABA/LAMA Comparator
Trough FeV1 (l) from baseline to
laBa/laMa versus laMa
Week 12 7, 15, 24–33 5,565 6,615 Mean difference 0.07 (0.05, 0.09) 91 (0.0001)
Week 24–26 15, 24–33 4,584 5,552 0.07 (0.05, 0.08) 56 (0.0001)
Week 52 24, 26, 27, 33 2,015 2,488 0.07 (0.05, 0.10) 63 (0.0001)
Total assessed for MCIDa 
Total with MCID
25, 29–31 1,765 2,240 relative risk 1.33 (1.20, 1.46) 55 (0.0001)
1,018 978 nnTB 8 (6, 9)
laBa/laMa versus laBa/ICs
Week 12 34–36, 39 3,142 3,123 Mean difference 0.08 (0.07, 0.09) 0 (0.0001)
Week 24–26 34–38 2,563 2,537 0.06 (0.00, 0.12) 90 (0.04)
Total assessed for MCID 
Total with MCID
35, 37, 38 1,371 1,383 relative risk 1.44 (1.33, 1.56) 0 (0.0001)
nnTB 6 (5, 7)
Peak FeV1 (l) from baseline to
laBa/laMa versus laMa
Week 12 28, 32 893 868 Mean difference 0.10 (0.08, 0.12) 0 (0.0001)
Week 24–26 25, 29–32 2,150 2,625 0.11 (0.09, 0.12) 0 (0.0001)
laBa/laMa versus laBa/ICs
Week 12 34, 35, 37, 38 1,552 1,544 Mean difference 0.12 (0.10, 0.14) 0 (0.0001)
Week 24–26 34, 35, 39 953 932 0.12 (0.09, 0.15) 62 (0.0001)
Note: aMCID 100 ml above baseline.
Abbreviations: CI, confidence interval; MCID, minimum clinically important difference; NNTB, number needed to treat for benefit; ICS, inhaled corticosteroid; LABA, 
long-acting β2-agonist; laMa, long-acting muscarinic antagonist; FeV1, forced expiratory volume in 1 second; TDI, transitional dyspnea index.
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LAMA-treated patients were 12% more likely to achieve an 
MCID in TDI (1 point increase) compared with LAMA-
treated patients (RR: 1.12; 95% CI: [1.06, 1.18]; Table 3), 
with an NNTB of 19 patients (95% CI: [12, 36]). The absolute 
proportions of patients achieving any MCID were 61% (1,500 
of 2,444) and 56% (1,604 of 2,865), respectively.
No statistically significant difference between LABA/
LAMA and LABA/ICS treatments with respect to TDI 
focal scores at weeks 12 and 26 were observed (P=0.09 and 
P=0.29, respectively; Table 3; Figure S6B), although a trend 
in favor of LABA/LAMA treatment was observed.
With respect to the effect of different treatments on 
health status, SGRQ total scores (mean difference from 
baseline) at the week 12 and 24 time points were significantly 
improved in LABA/LAMA- versus LAMA-treated patients 
(mean difference: -1.84, 95% CI: [-2.31, -1.37], and mean 
difference: -1.34, 95% CI: [-1.94, -0.75] points, respec-
tively, both P0.0001; Table 3; Figure S7A [i] and [ii]). 
By week 52, the intertreatment difference was no longer 
statistically significant (mean difference: -1.21, 95% CI: 
[-2.64, 0.21], P=0.09; Table 3; Figure S7A [iii]), although the 
direction of the treatment benefit remained in favor of LABA/
LAMA treatment. Furthermore, SGRQ scores at week 52 
were only captured in three studies, compared with 11 and 8 
in the earlier time points; therefore, this finding may not be 
as robust as the earlier time points because the end point was 
tested in a comparatively smaller population. Heterogeneity 
between the three trials comprising the week 52 end point was 
also relatively high, at an I2 of 58%. In studies where MCID 
was evaluated, at the end of treatment, LABA/LAMA-treated 
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Figure 2 Pooled mean difference for trough FeV1 (change from baseline, l) at week 12, with 95% CIs, for eligible studies comparing approved doses of laBa/laMa 
combinations with approved laMas.
Abbreviations: CI, confidence interval; FEV1, forced expiratory volume in 1 second; laBa, long-acting β2-agonist; laMa, long-acting muscarinic antagonist; sD, standard 
deviation; IV, intravenous; od, once daily; bid, twice daily.
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patients were found to be 14% more likely to have achieved 
an MCID in SGRQ (4 unit decrease) than LAMA-treated 
patients (RR: 1.14, 95% CI: [1.09, 1.20]); the NNTB was 
16 (95% CI: [12, 22]) (Table 3). The absolute proportions 
of patients achieving any MCID were 56% (2,493 of 4,450) 
and 50% (2,668 of 5,385), respectively.
Overall, no statistically significant difference was 
observed between LABA/LAMA and LABA/ICS treat-
ments with respect to SGRQ total score at week 12 (mean 
difference: -0.43, 95% CI: [-1.28, 0.42], P=0.32), poten-
tially driven by the considerable heterogeneity between the 
trials, providing an overall I2 of 48%. At week 26, SGRQ 
scores had significantly improved in LABA/LAMA- versus 
LABA/ICS-treated patients (mean difference: -1.13, 95% 
CI: [-1.78, -0.48], P=0.0006; Table 3; Figure S7B), an 
effect driven by the data of the Ind/Gly data available at that 
time point. Interestingly, the trial that contributed the greatest 
weight to the analysis of this comparison, FLAME,36 was 
highly significantly in favor of LABA/LAMA at both time 
points (Figure S7B).
At the end of treatment, rescue medication use rela-
tive to baseline use was significantly reduced in LABA/
LAMA-treated patients compared with those treated with 
either LAMA or LABA/ICS (reduction of -0.58 puffs/day, 
95% CI: [-0.70, -0.45]; P0.0001; and -0.18 puffs/day, 
95% CI: [-0.28, -0.07], P=0.001, respectively) (Table 3; 
Figure S8).
effect of treatments on COPD 
exacerbations and hospitalizations
There were insufficient data to conduct a meta-analysis on 
the effect of treatment on prospectively collected COPD 
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Figure 3 Pooled mean difference for trough FeV1 (change from baseline, l) at (A) week 12 and (B) weeks 24–26, with 95% CIs, for eligible studies comparing approved 
laBa/laMa combinations with approved laBa/ICs combinations.
Abbreviations: CI, confidence interval; FEV1, forced expiratory volume in 1 second; laBa, long-acting β2-agonist; laMa, long-acting muscarinic antagonist; se, standard 
error; od, once daily; bid, twice daily; FP, fluticasone propionate.
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exacerbation rates in LABA/LAMA- versus LAMA-treated 
patients because such data were available in only one study.26 
However, compared with LABA/ICS treatment, LABA/
LAMA significantly reduced the annualized rate of moderate 
and/or severe exacerbations (RR: 0.82, 95% CI: [0.75, 0.91]; 
P0.001; Figure 4A). A trend in favor of LABA/LAMA 
was also observed for severe exacerbations alone, with one 
study35 revealing a significant benefit in favor of LABA/
LAMA, and another36 showing a numerical benefit. However, 
heterogeneity between the two studies was high for this end 
point, at I2=74% (Figure 4B).
effect of treatments on safety outcomes
The relative effects of each COPD treatment class on the 
safety end points of AE and SAE incidence, numbers of 
withdrawals (due to AEs or lack of efficacy) and deaths, as 
well as the effect of treatment on annualized exacerbation 
rate, are presented in Table 4.
No significant difference in the incidence of AEs was 
observed in patients treated with LABA/LAMA combinations 
versus those on LAMA monotherapy (RR: 1.00, 95% CI: 
[0.98, 1.02], P=0.95; Table 4; Figure 5A). Likewise, no sig-
nificant difference in the incidence of SAEs (RR: 1.01, 95% 
CI: [0.88, 1.15], P=0.94) nor in the incidence of pneumonia or 
cardiovascular-related events (RR: 1.04, 95% CI: [0.78, 1.38], 
P=0.79, and RR: 1.09, 95% CI: [0.77, 1.55], P=0.62, respec-
tively; Figures S9A, S10 and S11A) was observed.
Compared with LABA/ICS treatment, however, LABA/
LAMA-treated patients had significantly lower AE rates (RR: 
0.94, 95% CI: [0.89, 0.99], P=0.02), with a number needed 
to treat for harm (NNTH) of 32 (95% CI: 18, 100) (Table 4; 
Figure 5B). There were significantly fewer incidences of 
pneumonia in the LABA/LAMA treatment arm versus the 
LABA/ICS treatment arm (RR: 0.59, 95% CI: [0.43, 0.81], 
P=0.001), with an NNTH of 84 (95% CI: 54, 184) (Table 4; 
Figure 6). Neither the incidence of SAEs nor cardiovascular-
related events were significantly different between the 
LABA/LAMA and LABA/ICS groups (RR: 0.90, 95% CI: 
[0.74, 1.10], P=0.32, and RR: 1.17, 95% CI: [0.78, 1.76], 
P=0.45, respectively; Figures S9B and S11B).
The overall rates of death were low across treatment 
groups, with no significant differences observed between 
patients treated with LABA/LAMA and those on either 
LAMA or LABA/ICS (P=0.46 and 0.65, respectively; 
Table 4; Figure S12).
The rate of withdrawal from treatment due to AEs was 
significantly lower in LABA/LAMA-treated patients com-
pared with those treated with LABA/ICS (RR: 0.83, 95% 
CI: [0.69, 0.99], P=0.05; Table 4) but not when compared 
with those treated with LAMA alone (Figure S13). However, 
significantly more LAMA- versus LABA/LAMA-treated 
patients withdrew due to lack of efficacy (RR: 0.66, 95% CI: 
[0.51, 0.87], P=0.003; NNTH 90, 95% CI: [56, 218]), with 
no such difference apparent between LABA/LAMA- and 
LABA/ICS-treated patients (Table 4; Figure S14).
Discussion
In this meta-analysis of 23 RCTs in 20,185 patients with 
stable moderate-to-very severe COPD, we compared 
the efficacy and safety of dual bronchodilation with four 
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Figure 4 Pooled relative risk of annualized rates of (A) moderate and/or severe exacerbations or (B) severe exacerbations, with 95% CIs, for eligible studies comparing 
approved laBa/laMa combinations with approved laBa/ICs combinations.
Note: Insufficient data prevented a similar analysis to be conducted versus approved LAMAs.
Abbreviations: CI, confidence interval; ICS, inhaled corticosteroid; FEV1, forced expiratory volume in 1 second; laBa, long-acting β2-agonist; laMa, long-acting muscarinic 
antagonist.
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approved LABA/LAMA FDCs (Ind/Gly, Umec/Vi, Acli/For 
and Tio/Olo) with treatment using LAMA or LABA/ICS. 
We have shown that LABA/LAMA combinations provided 
superior efficacy and comparable safety profiles compared 
with either LAMA or LABA/ICS treatment.
The efficacy and safety of LABA/LAMA combinations 
has been evaluated in previous meta-analyses.13,14,40 Single 
LABA/LAMA combinations have been evaluated in two 
studies,13,14 whereas in a recent meta-analysis,40 all doses 
of LABA/LAMA combinations were pooled and treatment 
effects were compared with the combined pooled effect of the 
monocomponents (LABA or LAMA) and not with LABA/
ICS combinations. In our analysis, we also pooled the data 
from trials using the same treatments and dose regimens to 
facilitate comparisons between treatment subgroups. Pooling 
of data in this manner is recommended in meta-analyses in 
which there are only a few studies per subgroup because 
estimates within subgroups are likely to be imprecise; in 
such instances, the increased accuracy obtained using pooled 
estimates is likely to exceed any real differences between 
groups in the true value. The difference in our analysis 
compared with previous analyses is that we included all 
Table 4 effect of laBa/laMa versus laMa or laBa/ICs on safety outcomes
Outcome measure Studies  
included
No of patients Relative risk
LABA/LAMA Comparator Effect (95% CI) I2, % (P-value)
any ae
laBa/laMa versus laMa 7, 15, 24–33 5,687 6,840 1.00 (0.98, 1.02) 0 (0.95)
laBa/laMa versus laBa/ICs 34–39 3,835 3,838 0.94 (0.89, 0.99)
nnTh: 32 (18, 100)
23 (0.02)
serious aes
laBa/laMa versus laMa 7, 15, 24–33 5,687 6,840 1.01 (0.88, 1.15) 21 (0.94)
laBa/laMa versus laBa/ICs 34–39 3,616 3,656 0.90 (0.74, 1.10) 18 (0.32)
Pneumonia
laBa/laMa versus laMa 7, 24–27, 29–32, 36 4,439 5,584 1.04 (0.78, 1.38) 0 (0.79)
laBa/laMa versus laBa/ICs 34–39 3,835 3,838 0.59 (0.43, 0.81)
nnTh: 84 (54, 184)
0 (0.001)
Cardiac/cardiovascular disorders
laBa/laMa versus laMa 24–31 3,533 4,679 1.09 (0.77, 1.55) 32 (0.62)
laBa/laMa versus laBa/ICs 34–39 3,835 3,838 1.17 (0.78, 1.76) 0 (0.45)
Deaths
laBa/laMa versus laMa 7, 15, 24–32 5,282 6,434 -0.00 (-0.00, 0.00) 0 (0.46)
laBa/laMa versus laBa/ICs 34–39 3,835 3,838 0.00 (-0.00, 0.00) 0 (0.65)
Withdrawals due to aes
laBa/laMa versus laMa 7, 15, 24–26, 28–33 5,300 6,448 0.97 (0.80, 1.18) 19 (0.78)
laBa/laMa versus laBa/ICs 34–39 3,836 3,841 0.83 (0.69, 0.99)
nnTh: 88 (45, 1,228)
0 (0.04)
Withdrawals due to lack of efficacy
laBa/laMa versus laMa 15, 25, 26, 28–33 3,947 5,173 0.66 (0.51, 0.87)
nnTh: 90 (56, 218)
0 (0.003)
laBa/laMa versus laBa/ICs 34–38 1,691 1,695 1.10 (0.60, 2.03) 0 (0.75)
Abbreviations: AE, adverse event; CI, confidence interval; NNTH, number needed to treat for harm; ICS, inhaled corticosteroid; LABA, long-acting β2-agonist; laMa, long-
acting muscarinic antagonist.
currently available LABA/LAMA combinations and chose 
only approved doses of these combinations and their com-
parators. Including all available LABA/LAMA combinations 
also allowed us to provide indirect insights on the potential 
relative efficacy of these drugs (although we also recognize 
that any conclusions drawn will need to be confirmed in 
prospective, head-to-head studies). In addition, we used as 
comparators the treatments most commonly prescribed in 
COPD clinical practice (ie, LAMAs or LABA/ICS). Finally, 
we elected to implement the robust methodology of a stan-
dard meta-analysis design that involved a direct, pooled 
analysis of LABA/LAMA with their comparators. Based 
on all of the above, we believe that our analysis provides 
clinically relevant, high-quality evidence that is applicable 
to daily clinical practice.
After 12 weeks of treatment, significant improvements 
in lung function (trough and peak FEV
1
) were observed with 
LABA/LAMA combinations compared with the results with 
LAMA or LABA/ICS. Furthermore, the percentage of LABA/
LAMA-treated patients achieving MCIDs in trough FEV
1
 
was significantly higher than that with LAMA or LABA/ICS, 
with NNTBs of 8 and 6, respectively. These magnitudes of 
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treatment effects and NNTBs are similar to those of previous 
meta-analyses comparing LABA/LAMA with LAMA and/or 
LABA/ICS10,14 and were maintained versus both comparators 
after longer periods of treatments (24–26 weeks or 52 weeks). 
Significant improvements in peak FEV
1
 relative to baseline 
measurements were also observed at week 12 for LABA/
LAMA treatment versus both comparators (mean differences 
of 0.1–0.2 L). As with trough FEV
1
, these improvements were 
still evident after several weeks of treatment.
Previous analyses have shown that improvements in FEV
1
 
are likely to be associated with improvements in patient-re-
ported outcomes in COPD patients.41 In our analysis, LABA/
LAMA versus LAMA alone improved the patient-reported 
outcomes of dyspnea (TDI) and HRQoL (SGRQ) at week 
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Figure 5 (Continued)
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Figure 5 Pooled relative risk of ae incidence at end of treatment, with 95% CIs, for eligible studies comparing approved doses of laBa/laMas with approved doses of 
(A) laMas and (B) laBa/ICs combinations.
Abbreviations: AE, adverse event; CI, confidence interval; ICS, inhaled corticosteroid; LABA, long-acting β2-agonist; laMa, long-acting muscarinic antagonist; 
M–h, Mantel–haenszel test.
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12; 28% and 14% of LABA/LAMA- versus LAMA-treated 
patients, respectively, were also more likely to achieve 
MCIDs in these outcome measures (NNTB: 26 and 16, 
respectively). LABA/LAMA-treated patients also had signifi-
cantly reduced requirements for rescue medications during 
the trial than both LAMA- and LABA/ICS-treated patients. 
A trend in favor of LABA/LAMA versus LABA/ICS treat-
ment was also observed with respect to TDI score and, for 
health status, a significant benefit in favor of LABA/LAMA 
was observed at week 26 but not at week 12 versus LABA/
ICS. These differences were mainly driven by the Ind/Gly 
trials; however, significant heterogeneity in component stud-
ies prevented firm conclusions to be drawn. As mentioned 
previously, LABAs improve symptoms and HRQoL more 
effectively than LAMAs, while LAMAs are superior to 
LABAs in reducing exacerbations.9,11 Given that the severity 
and frequency of exacerbations are associated with impaired 
HRQoL,42 the improvements in HRQoL with LABA/LAMA 
versus LABA/ICS were more evident in studies including 
patients with more severe exacerbations.36
A protocol-defined end point of this meta-analysis was 
to examine the annualized rate of COPD exacerbations 
prospectively collected as an efficacy end point. Only 
three studies (two LABA/LAMA versus LABA/ICS 
comparisons35,36 and one LABA/LAMA versus LAMA 
comparison26) prospectively collected exacerbation rates, 
and therefore a meta-analysis of LABA/LAMA versus 
LAMA was not possible. Nevertheless, a positive signal 
for LABA/LAMA versus LAMA treatment was evident in 
the SPARK study,26 and the inclusion of data from ongoing 
studies such as DYNAGITO (Tio/Olo versus Tio) will clarify 
the role of LABA/LAMA versus LAMA treatment in the 
prevention of COPD exacerbations, especially in high-risk 
populations. Compared with LABA/ICS, however, LABA/
LAMA treatment significantly reduced the rate of moderate 
and/or severe exacerbations, and a trend in favor of LABA/
LAMA was also observed for reducing severe exacerbations. 
Whether this finding represents an effect of Ind/Gly, which 
was the comparator LABA/LAMA used in the two evaluated 
studies,35,36 or an overall effect of the LABA/LAMA class 
needs to be defined in prospective studies using the other 
available combinations.
AE incidence was significantly lower in LABA/LAMA- 
versus LABA/ICS-treated patients (NNTH =32), with the 
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excess in the LABA/ICS arm plausibly related to the ICS 
component. This difference, however, did not translate 
through to SAEs, with no significant differences in SAE 
incidence observed between LABA/LAMA- and either 
LABA/ICS- or LAMA-treated patients. The incidence 
of pneumonia, however, was significantly lower in the 
LABA/LAMA group versus the LABA/ICS-treated patients 
(RR: 0.34). Several studies and systematic reviews compar-
ing pneumonia risk in patients receiving ICS alone or in 
combination with LABA have reported a greater incidence 
of pneumonia in the LABA/ICS or ICS arms relative to the 
LABA arm.5,43 Regarding potential differences between dif-
ferent ICS treatments, some evidence of a higher risk of any 
pneumonia event has been reported with fluticasone versus 
budesonide, but no significant differences between the two 
drugs were observed in terms of SAEs (either pneumonia-
related or all-cause) or mortality.44 In the studies included in 
the current analysis, salmeterol/fluticasone propionate was 
the only LABA/ICS used as a comparator; therefore, in our 
systematic review, we were not able to provide additional 
data in this regard.
Cardiovascular events were also of particular interest as 
single-agent LABAs have been associated with increased risk 
of arrhythmias,45 whereas retrospective analyses of LABA/
ICS studies have shown a potential benefit for LABA/ICS 
on the risk of cardiovascular AEs versus placebo.46 A recent 
study demonstrated that LABA/ICS did not reduce mortality 
versus LABA/placebo in patients with, or at risk of, car-
diovascular events,47 disputing the notion that ICS-induced 
decreases in systemic inflammation can reduce mortality. In 
the current analysis, no significant differences were observed 
between any of the treatment classes with respect to cardiac or 
cardiovascular disorders; this is in accordance with a pooled 
analysis of safety data showing no increase in the risk of 
major cardiovascular events in COPD patients treated with 
LABA/LAMA (Ind/Gly) versus placebo (RR: 1.04, 95% 
CI: [0.45, 2.42]).48
Withdrawals due to AEs were significantly higher in 
LABA/ICS-treated patients compared with LABA/LAMA-
treated patients, presumably due to AEs of pneumonia or 
other respiratory or extrapulmonary events associated with 
ICS use. Indeed, a significantly higher incidence of pneumo-
nia (P=0.02) was observed in the LABA/ICS arm of one of 
the composite studies included in this meta-analysis, while a 
threefold higher incidence was reported in other studies.35,36 
Withdrawals due to lack of efficacy, however, occurred in 
Figure 6 Pooled relative risk of pneumonia incidence, with 95% CIs, for eligible studies comparing approved doses of laBa/laMas with approved doses of laBa/ICs 
combinations.
Abbreviations: CI, confidence interval; ICS, inhaled corticosteroid; LABA, long-acting β2-agonist; laMa, long-acting muscarinic antagonist; M–h, Mantel–haenszel test.
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significantly more LAMA- versus LABA/LAMA-treated 
patients, a finding that was driven largely by two of the 
component trials.26,31
There are certain potential limitations in the current 
analysis. 1) Open-label tiotropium was used as comparator 
in some studies;24,26 this may have affected patient-reported 
outcomes (TDI and SGRQ), although it should not bias 
objective outcomes such as FEV
1
. 2) As our sample was 
largely composed of patients with stable COPD and infre-
quent exacerbations, our findings cannot readily be applied 
to all patients with frequent exacerbations; nevertheless, 
a significant proportion of patients with frequent exacerba-
tions were included in the two studies that evaluated exac-
erbations as an outcome.26,36 3) In this analysis, we do not 
provide any comparisons of LABA/LAMA versus LABA, 
as we wanted to evaluate the available evidence compared 
with the most commonly prescribed medications for COPD, 
namely, LABA/ICS or LAMA. That said, however, the 
recent network meta-analysis by Oba and Lone16 did include 
this comparison, finding LABA/LAMA combinations to be 
associated with significantly improved efficacy outcomes 
versus LABAs while maintaining similar safety profiles. 
4) Based on the design of the studies identified for this sys-
tematic review, we are unable to provide data on outcomes 
beyond 52/64 weeks or on mortality or disease progression. 
Further studies using LABA/LAMA combinations are 
required to address these important scientific questions. 
5) Given the heterogeneity of COPD, it would have been 
of interest to evaluate further parameters such as additional 
spirometric measures (eg, forced vital capacity [FVC]49 or 
other markers of small airways dysfunction) or the effects of 
treatments on physical activity.50,51 Data on such parameters 
are, however, not uniformly presented in RCTs; therefore, 
in this meta-analysis, the most commonly used clinically 
relevant outcomes were prespecified as the outcomes of 
interest. 6) Definitive conclusions on the relative efficacy of 
different treatments within the LABA/LAMA class cannot be 
made as the individual treatments were not compared head to 
head. Nevertheless, we observed differences between differ-
ent drugs, and the clinical significance of these differences 
needs to be further evaluated.
Conclusion
This meta-analysis of 23 RCTs provides evidence that LABA/
LAMA FDCs offer superior efficacy and comparable safety 
to LAMA or LABA/ICS in patients with stable moderate-
to-very severe COPD, indicating their potential as first-line 
treatment options for this population of patients.
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